Phase 3, randomised double-blind, placebo-controlled, multicentre trial assessing the impact of Lp(a) lowering with pelacarsen on major cardiovascular events in patients with established cardiovascular disease
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
